Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Efficacy of Bevacizumab-Capeci...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer

Show other versions (1)
Bibliographic Details
Main Authors: Stephen Dyar, Alvaro Moreno-Aspitia
Format: Article
Language:English
Published: SAGE Publishing 2011-11-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:http://www.la-press.com/efficacy-of-bevacizumab-capecitabine-in-combination-for-the-first-line-a2932
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

http://www.la-press.com/efficacy-of-bevacizumab-capecitabine-in-combination-for-the-first-line-a2932

Similar Items

  • Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
    by: Stephen Dyar, et al.
    Published: (2011-01-01)
  • Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal carcer
    by: Jungić Saša, et al.
    Published: (2017-01-01)
  • Combination capecitabine and bevacizumab in the treatment of metastatic hepatic epithelioid hemangioendothelioma
    by: Augustine Lau, et al.
    Published: (2015-07-01)
  • Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
    by: Miao-Zhen Qiu, et al.
    Published: (2024-12-01)
  • Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    by: Yeong Hak Bang, et al.
    Published: (2021-03-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs